Status | Study |
Recruiting |
Study Name: Prospective Cohort for Adult Hemophagocytosis Condition: Hemophagocytic Lymphohistiocytoses Date: 2017-04-12 Interventions: Drug: Steroids High dose dexam |
Recruiting |
Study Name: L-DEP as an Initial Treatment for EBV-HLH Condition: Hemophagocytic Lymphohistiocytosis Date: 2016-09-09 Interventions: Drug: Pegaspargase 2000U/m2 da |
Recruiting |
Study Name: Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology Condition: Hemophagocytic Lymphohistiocytosis Date: 2016-08-06 Interventions: Procedure: splenectomy |
Completed |
Study Name: The Prognostic and Diagnostic Value of Ferritin in Critically Ill Patients With Special Focus on Underlying Hemophagocytic Lymphohistiocytosis Condition: Hemophagocytic Lymphohistiocytosis Date: 2016-08-01 |
Recruiting |
Study Name: L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis Condition: Hemophagocytic Lymphohistiocytosis Date: 2015-12-03 Interventions: Drug: Pegaspargase 2000U/m2 da |
Recruiting |
Study Name: Treatment of Familiar Lymphohistiocytosis Condition: Hemophagocytic Lymphohistiocytosis (HLH) Date: 2015-06-08 Interventions: Drug: Alemtuzumab Other Name: |
Recruiting |
Study Name: Alemtuzumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Condition: Leukemia Date: 2015-03-05 Interventions: Drug: Alemtuzumab |
Recruiting |
Study Name: A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome Condition: Hemophagocytic Syndrome (HPS) Date: 2015-01-22 Interventions: Drug: Ruxolitinib |
Recruiting |
Study Name: Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases Condition: Primary Immune Deficiency Disorders Hemophagocytic Lymphohistiocytosis Date: 2014-08-28 Interventions: Biological: BPX-501 and AP1903 Single administration of BPX-501 T cells post partially-mismatched, relat |
Recruiting |
Study Name: Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody Condition: Hemophagocytic Lymphohistiocytosis Date: 2013-12-23 Interventions: Drug: NI-0501 In the event that NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the pr |